Praxis Precision Medicines, Inc. (PRAX) Earnings
Praxis Precision Medicines, Inc. is expected to report next earnings on August 3, 2026 (in NaN days), with a consensus EPS estimate of $-3.67. PRAX has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise -1.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-3.58 | $-3.20 | +10.6% | — | — |
| Feb 19, 2026 | $-3.00 | $-3.50 | -16.7% | — | — |
| Nov 5, 2025 | $-3.45 | $-3.36 | +2.6% | — | — |
| May 2, 2025 | $-3.20 | $-3.29 | -2.8% | — | — |
| Feb 28, 2025 | $-2.76 | $-2.94 | -6.5% | $7M | +2405.4% |
| Aug 13, 2024 | $-2.38 | $-1.74 | +26.9% | $357000 | -57.0% |
| Mar 5, 2024 | $-3.15 | $-2.97 | +5.7% | $515000 | +930.0% |
| May 11, 2023 | $-11.24 | $-10.64 | +5.3% | $683000 | — |
| Feb 7, 2023 | $-10.94 | $-13.04 | -19.2% | — | — |
| Nov 9, 2022 | $-13.79 | $-14.39 | -4.4% | — | — |
| Feb 28, 2022 | $-16.19 | $-19.49 | -20.4% | — | — |
| Nov 3, 2021 | $-13.94 | $-14.99 | -7.5% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Marcio Souza discussed continued execution across portfolio with four late-stage assets, NDAs accepted by FDA for some drugs, ramping up commercial efforts, completion of Emerald study enrollment, progress in clinical programs including vormetrogene and alginersin, key hires in commercial organization, and launch preparations. Tim Kelly provided financial summary with operating expenses, cash used in operations, and cash position as of March 31, 2026
Guidance
Expect top-line results from Emerald study in 4Q 2026, PowerOne study for vormetrogene later this quarter, completion of Power2 study later in year, and preparations for commercial launches of elixir-cultamide and relutrigine within next eight months. Cash expected to fund operations into 2028
Segment performance
Discussed progress across product segments including Ulexa with NDA accepted by FDA, epilepsy programs with NDA accepted and recruitment in Emerald study, vormetrogene with upcoming study results, and alginersin with positive trial results. Financials mentioned operating expenses and cash position but segment performance focus on program progress
Risks & headwinds
None explicitly discussed in detail
Analyst Q&A
Q: Questions about Emerald study data, vormetrogene readout, Ulexa regulatory interactions, etc.
A: Marcio and other executives answered regarding study details, expectations, regulatory communication, patient population heterogeneity, commercialization plans, etc.